

Chiesi (UK Limited) and Manchester Royal Infirmary Executive Summary

This summary has been written by Chiesi Limited with consultation and approval from the Collaborative Working Project Team, established with full representation of partners.

Post-Transplant Initiative for Optimising Nurse-led Engagement & Empowering Recovery (PIONEER)

Aim

To undertake a nurse led clinic that identifies (with appropriate, agreed clinical and demographical criteria) targeted post-transplant patient populations that sit within low social economic / low index multiple deprivation locations who may benefit from personalised pharmacological and non-pharmacological support and guidance.

The intended objectives of this collaborative project are to:

- Review the assessment of the targeted patient population with an aim to provide personalised pharmacological and non-pharmacological advice, guidance and treatment.
- Implementation of a nurse led clinic for appropriate patients (as per operational group agreement)
- Evaluation of nurse led clinical evaluation of improvement and patient reported outcome measures (PROMS), patient reported experience measures (PREMS) to assess quality of life and experiences
- Provide a lessons learned/framework for scale and spread at local level and beyond

Intended Benefits

For Patients:

- Management of care that includes a personalised approach
- Shared decision making in post-transplant care
- Opportunities to have their voices represented

NHS:

- Improved healthcare resource utilisation
- Identification of patients suitable for medicines optimisation
- Personalised pharmacological and non-pharmacological interventions for patients to ensure they are appropriately optimised whilst reducing risks associated with long term medication exposure.

For industry partner:

- Better understanding of challenges faces by the NHS in delivering high-quality patient care.
- Gain a better understanding of patient needs, identifying what patients value most in their post-transplant management to tailor treatments and education accordingly.
- Growth of patient population eligible for alternative formulations of tacrolimus.
- Reputational gain associated with supporting improvements in NHS services and care by enabling NHS pathway change

This involves a balance of contributions from both parties with the pooling of skills, experience, and resources.

The project will last 24 months and will commence May 2025.